Collegium Pharmaceutical (COLL) Cash & Current Investments (2014 - 2026)

Collegium Pharmaceutical has reported Cash & Current Investments for 13 years, with the latest figure at $149.3 million in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 32.79% year-over-year to $149.3 million in Q2 2026; TTM through Jun 2026 was $149.3 million, a 32.79% decrease from a year earlier, with the FY2025 full-year figure at $386.7 million, up 137.57% from the prior year.
• Cash & Current Investments was $149.3 million for Q2 2026 at Collegium Pharmaceutical, down from $421.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $421.8 million in Q1 2026, with the low at $106.7 million in Q1 2022.
• Average Cash & Current Investments over 5 years is $238.0 million, with a median of $245.8 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments jumped 165.21% in 2023, then slumped 60.61% in 2024.
• Over 5 years, Cash & Current Investments stood at $173.7 million in 2022, then jumped by 78.8% to $310.5 million in 2023, then sank by 47.59% to $162.8 million in 2024, then soared by 137.57% to $386.7 million in 2025, then plunged by 61.38% to $149.3 million in 2026.
• The last three Cash & Current Investments figures came in at $149.3 million (Q2 2026), $421.8 million (Q1 2026), and $386.7 million (Q4 2025), per Business Quant data.